Betalin’s Micro-Pancreas to ‘Cure’ Diabetes Ready for UK Trials
Jerusalem based Betalin Therapeutics will be submitting a request to Britain’s regulatory agency in August for human clinical trials in the UK, for their Endocrine
NOBIO COVID-19 Personal Protection Coatings Awarded Israel Innovation Authority Grant
Nobio was recently awarded a $205,000 grant from the Israel Innovation Authority to rapidly develop personal protection and surface coatings with long acting, universal protection
Yissum Spinouts Raise Record $79 million in H1 2020 Despite Coronavirus
(July 28, 2020– Jerusalem) Startups from The Hebrew University of Jerusalem raised $79 million in the first half of 2020, Yissum, the technology transfer company
New Israeli Trial on Possible Pomegranate Oil Prevents Age Related Brain Decline
Jerusalem based Granalix is to be teaming up with the Rambam Medical Center’s Memory Clinic on a new clinical trial to test the impact of
Oramed Oral Insulin for Treatment of Diabetes Gets 3rd Phase Clinical Trials Greenlight
The Need Diabetes and its prevalence in modern society have been a major international health concern for some time. Health officials worldwide have seen the
Anchiano Appoints Stan Polovets as Chairman of the Board
Anchiano Therapeutics Ltd. (Nasdaq: ANCN) (“Anchiano”) recently announced that Mr. Stan Polovets has been elected chairman of its board of directors. Mr. Polovets joined the
Gamida Cell Adds David Fox to Board of Directors
Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced that David
JLM Immuno-Oncology Company Nectin raises $6m from Amoon
Nectin Therapeutics is developing a number of antibodies that can enhance the treatments being offered to cancer patients. Jerusalem immuno-oncology biotherapies company Nectin Therapeutics has
Atox Bio’s Reltecimod Effective in Phase 3 Clinical Trials against Flesh Eating Disease
Reltecimod is Atox Bio‘s lead product in development and is currently in late stage clinical trials for Necrotizing Soft Tissue Infections (NSTI) (Flesh Eating Disease)
